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Abstract 
Inflammatory response is a principal early component in the pathophysiology of stroke [1]. Serum 
procalcitonin (PCT)-a marker of septicemia and infection severity [2]-has also been proposed as an 
indicator of systemic inflammatory response in noninfectious situations [3,4]. As no data exist thus far on 
PCT in stroke, this study aimed to evaluate serum PCT changes in the acute stroke setting, and to 
correlate them with clinical and laboratory parameters and patient's outcome. 
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Letter to the Editor
Serial serum procalcitonin changes in the
prognosis of acute stroke
To the Editor:
Inflammatory response is a principal early compo-
nent in the pathophysiology of stroke [1]. Serum
procalcitonin (PCT)—a marker of septicemia and
infection severity [2]—has also been proposed as an
indicator of systemic inflammatory response in non-
infectious situations [3,4]. As no data exist thus far on
PCT in stroke, this study aimed to evaluate serum
PCT changes in the acute stroke setting, and to
correlate them with clinical and laboratory parameters
and patient’s outcome.
All consecutive patients admitted with first-ever
stroke during a 3-month period were included.
Exclusion criteria included resolution of symptoms
within 24 h (TIA), coexistence of a chronic illness and
presence of Tz37.8 8C or evidence of coexisting
infection upon presentation.
For all patients, demographic data and risk factors
for stroke were recorded. Thirty patients (14 males, 16
females) were eligible for the study, mean age 77.8
years old. At presentation and at day 7, the Glascow
Coma Scale (GCS), the National Institute of Health
Stroke Scale (NIHSS), and the Acute Physiology And
Chronic Health Evaluation (APACHE) II score (only
on admission) were performed, and full blood count,
fibrinogen, C-reactive protein (CRP), glucose, urea,
creatinine, electrolytes, albumin, total protein, lipids,
creatine kinase (CK), lactate dehydrogenase (LDH)
and PCT were measured. PCT was also measured on
days 2, 3 and 4, since serum PCT levels reach their
peak between 48 and 72 h [3,4]. An axillary temper-
ature measurement was taken every 3 h in all patients.
PCT levels were measured by the use of an
immunoluminometric assay (Brahms Diagnostica,
Berlin, Germany). The lower limit of detection of
the assay was 0.08 ng/mL. With this assay, serum
levels of PCT in healthy adults were less than 0.1 ng/
mL [2,4]. Laboratory values were reported as the
median values on each measurement day. A two-sided
p value b0.05 was considered as statistically signifi-
cant. The study protocol was approved by our
Institutional Ethics Committee.
The main characteristics of serum PCT levels are
shown in Fig. 1. The highest median PCT level were
recorded on days 2 and 3 (0.17 and 0.18 ng/ml,
respectively). No statistically significant differences
were observed for the comparison of PCT values
between individual days. Nine patients (30%)
exhibited serum PCT levels not exceeding the lower
detection limit of the method on any measurement day.
In seven patients (23%) PCT levels reached their peak
at day 7. A statistically significant association was
observed between cases exhibiting peak PCT levels at
day 7 and the presence of fever (P-value 0.043, Mann–
Whitney test). Analyzing the 13 patients with fever
separately, median PCT levels at day 7 were higher for
eight patients with documented infection, but the
difference could not reach statistical significance.
Three patients suffered a brain hemorrhage, whereas
27 had a diagnosis of ischemic stroke. Nine patients
(30%) succumbed due to stroke or to related compli-
cations during the 30-day period following the attack.
Among the 21 survivors, 8 (38%) were functionally
independent on discharge (Modified Rankin Scale V3).
No correlations were recorded between PCT levels and
death, neurologic outcome on discharge or stroke type.
In contrast with PCT, APACHE II score ( p=0.002),
NIHSS score ( p=0.001), GCS score ( p=0.001) and
serum CK ( p=0.028) on admission and at day 7 (data
not shown), serum LDH at day 7 ( p=0.042), stroke
subtype ( p=0.004) and the presence of fever ( p=0.020)
were all significantly associated with stroke mortality.
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Neurologic outcome correlated with APACHE II score
and GCS score on admission, NIHSS score on
admission and at day 7, as well as with CK at day 7
(data not shown).
This was a pilot study on the prognostic value of
PCT in acute stroke. Serial serum PCT levels did not
correlate with stroke mortality or neurologic outcome
at discharge. Studies have correlated laboratory
parameters with prognosis in acute stroke, sometimes
with conflicting results [5–7]. Prognostic utility of
laboratory parameters in acute stroke is limited by the
need to perform serial measurements, together with the
interrelation of at least some of the inflammatory
markers. Hence, determination of stroke severity by
clinical criteria and appropriate imaging techniques
remains the main prognostic tool in acute stroke
settings [8], and the optimal biochemical marker (if
any) is still unknown.
The present study clearly shows that serum PCT is
not candidate for such a marker. Small sample size
and analytical restrictions of the assay constitute the
main limitations of the present study. However, the
immunoluminometric method for PCT measurement
is widely accepted and was used to establish the role
of PCT in sepsis [2]. Moreover, other parameters and
clinical scoring systems examined in this study did
correlate with outcome, regardless of the small
number of cases.
Increased serum PCT levels imply for an infectious
origin of fever complicating an underlying non-
Fig. 1. Evolution of serum Procalcitonin (PCT) levels, as well as peak serum PCT levels for the patients of the study. Results are depicted as
median (bold horizontal line), 25th–75th percentiles (box) and 90th percentiles (plot lines). Cases that are outliers (with values between 1.5 and
3 box lengths from the upper edge of the box) are represented with circles (o), whereas extremes (cases with values more than 3 box lengths
from the upper edge of the box) are illustrated as asterisks (*). For each case series, are also given the number of valid cases, the median, the
minimum and maximum values, as well as the number of cases with values below the PCT detection limit. *Not statistically significant
differences between the median of dead and alive patients.
Letter to the Editor238
infectious febrile disease [9,10]. The present study was
not designed to examine PCT as a marker of
intercurrent infections in stroke. Nevertheless, correla-
tion of fever with cases exhibiting peak PCT levels at
day 7 might imply for a role of PCT in identifying a
subset of stroke patients, which later develop fever due
to infection. In this study such a hypothesis could not
be sustained due to insufficient sample size. A future
larger study, examining serial PCT changes after fever
onset, might answer whether PCT can serve as marker
of bacterial infections complicating stroke.
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